$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Antibodies are composed of two identical heavy chains and two light chains that are responsible for the antigen binding. Camelids have heavy-chain only antibodies that exhibit similar affinity for their cognate antigen compared to conventional antibodies1,2. The single variable domain (VHH) of heavy-chain only antibodies retain the full antigen-binding potential and has been shown to be very stable1,2. These isolated VHH molecules or "nanobodies" have been implemented in studies related to membrane proteins biochemistry as tools for stabilizing conformations3,4, as inhibitors5,6, as stabilization agents7, and as gadgets for structure determination8,9,10. Nanobodies can be generated by the immunization of camelids for the pre-enrichment of B-cells that encode target-specific nanobodies and subsequent isolation of B cells, followed by cloning of the nanobody library and selection by phage display11,12,13. An alternate way to generate nanobodies is based on in vitro selection methods that rely on the construction of libraries and selection by phage display, ribosome display, or yeast display14,15,16,17,18,19,20. These in vitro methods require large library sizes but benefit from avoiding animal immunization and favor the selection of nanobodies targeting proteins with relatively low stability.
The small size of nanobodies, their high stability and solubility, strong antigen affinity, low immunogenicity, and relatively easy production, make them strong candidates for the development of therapeutics21,22,23. In particular, nanobodies inhibiting the activity of multiple membrane proteins are potential assets for clinical applications5,24,25,26. In the case of membrane transporters, to evaluate whether a nanobody has inhibitory activity, it is necessary to develop an assay that allows the detection of transported substrates and/or co-substrates. Such assays usually involve labeled molecules or the design of substrate-specific detection methods, which may lack a universal application. Furthermore, the identification of inhibitory nanobodies generally requires the screening of large numbers of binders. Thus, a method that can be used in a high-throughput mode and that does not rely on labeled substrates is essential for this selection.
SSM-based electrophysiology is an extremely sensitive, highly time-resolved technique that allows the detection of movement of charges across membranes (e.g., ion binding/transport)27,28. This technique has been applied to characterize electrogenic transporters, which are difficult to study using other electrophysiology techniques due to the relative low turnover of these proteins29,30,31,32,33,34,35. SSM electrophysiology does not require the use of labeled substrates, it is suitable for high-throughput screening, and either proteoliposomes or membrane vesicles containing the transporter of interest can be used. Here, we demonstrate that SSM-based electrophysiology can be used to classify transporter-targeted nanobodies with inhibitory and non-inhibitory properties. As a proof-of-principle, we describe the reconstitution of a bacterial choline transporter into liposomes, followed by detailed steps for immobilization of proteoliposomes on the SSM sensors. We next describe how to perform SSM-based electrophysiology measurements of choline transport and how to determine the half-maximal effective concentration (EC50). We then show how to use SSM-based electrophysiology to screen multiple nanobodies and to identify inhibitors of choline transport. Finally, we describe how to determine the half maximal inhibitory concentrations (IC50) of selected inhibitory nanobodies.